The company’s lead molecule, DI-Leu16-IL2, is a second-generation immunocytokine being tested in human clinical trials for treatment CD20-positive hematological cancers. This molecule has benefited from improvements made to the original technology that allow the molecule to have long circulation in the blood, and to have low immunogenicity , so the patient’s immune system does not recognize it as a foreign molecule.

 

DI-Leu16-IL2 has been partnered with Alopexx Enterprises for further clinical development in non-Hodgkin’s Lymphoma patients.

 

A jointly owned company, Alopexx Oncology, has been formed and is conducting clinical trials at multiple sites